Dosage optimization in drug development: An FDA Project Optimus analysis of postmarketing requirements issued to repair the cracks.

Author:

Heiss Brian1,Pan Lili1,Akalu Alemayehu1,Vallejo Jonathon1,Cheng Joyce1,Balcazar Pamela2,Rahman Nam Atiqur1,Shord Stacy Shifflett1,Shah Mirat1,Pazdur Richard2,Theoret Marc2

Affiliation:

1. Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD

2. Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, MD

Abstract

1598 Background: Dosage optimization (DO) is a critical aspect of oncology drug development. Because of this, the US FDA, through Project Optimus, has focused on reforming the DO and dosage selection paradigm for oncology products. When approving products, FDA may determine that although the recommended dosage possesses a favorable benefit:risk (BR) profile, there are significant safety concerns that require evaluation of alternative dosages to potentially improve the BR profile. Such postmarketing requirements (PMRs)—issued as a condition of approval—are examined here to better understand the characteristics and potential limitations of DO studies in the postmarketing setting. Methods: Between Jan. 1, 2010 to Dec. 31, 2022, oncology new molecular entities (NMEs) and original applications for biologics, hereafter referred to as new drugs, approved by CDER with at least one PMR issued for DO were identified in the FDA electronic records database. The designs and results of the associated trials or analyses for these PMRs, along with the status of the PMRs, were collected and evaluated. Results: There were 24 PMRs issued for 21 new drugs (15% of 138 total approved new drugs). The most common drug classes were: tyrosine kinase inhibitors (TKIs) (10), antibody drug conjugates (ADCs) (3), or GTPase Inhibitors (2). The following trials or analyses were planned to address these PMRs: randomized dose-comparison trials (18), non-randomized dose-finding trials (2), food effect trials (2), exposure-response analysis (1), and pending (1). The planned sample sizes for the 18 dose-comparison trials were 3 with <100 patients, 4 with 100 to 199 patients, 7 with 200 to 500 patients, and 4 with >500 patients. The dose-comparison trials used the following (co)primary endpoints: response rate (12), safety (7), OS (3), and PFS (2). Fourteen PMRs were either fulfilled (11) or released (3). Of the 11 fulfilled PMRs, 8 led to dosage changes for 5 new drugs (cabazitaxel, carfilzomib, ponatinib, ceritinib, and pexidartinib), and 3 did not lead to dosage changes. Ten PMRs are ongoing. The median time from issuance to fulfillment or release (not including ongoing PMRs) was 6 years (range: 0.7 to 8.3). Conclusions: A high proportion (15%) of new drugs required a PMR, which generally involved conducting a randomized trial with a substantial patient enrollment to evaluate an alternative dosage(s). This process was slow with a median of 6 years to fulfill a PMR. DO in the premarket setting has the potential to rapidly maximize BR, avoiding both patient exposure to unnecessary toxicity and large, resource-intensive, multi-year postmarketing trials. Project Optimus is working with stakeholders to advance a DO paradigm that occurs early and throughout premarket development to ensure an optimized recommended dosage at the time of approval.

Funder

None.

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3